Update on gout 2012

Joint Bone Spine

Volumn 79, Issue 6, 2012, Pages 539-543

  So, Alexander ^a   Busso, Nathalie ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Gout

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALLOPURINOL; C REACTIVE PROTEIN; CANAKINUMAB; COLCHICINE; CRYOPYRIN; FEBUXOSTAT; INFLAMMASOME; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; PEGLOTICASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PREDNISONE; PROTEIN KINASE SYK; REACTIVE OXYGEN METABOLITE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; TRIAMCINOLONE; TUMOR NECROSIS FACTOR ALPHA; URATE;

CLINICAL FEATURE; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DIZYGOTIC TWINS; DRUG SAFETY; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; GENE LOCUS; GENETIC ASSOCIATION; GOLD STANDARD; GOUT; HUMAN; HYPERTENSION; HYPERURICEMIA; INFLAMMATION; MONOZYGOTIC TWINS; PHENOTYPE; POLARIZATION MICROSCOPY; RADIODIAGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY AND SPECIFICITY; SHORT SURVEY; URIC ACID BLOOD LEVEL;

DISEASE MANAGEMENT; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY; URIC ACID;

EID: 84870665522     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2012.09.005     Document Type: Short Survey

References (37)

1. Singh J.A., Hodges J.S., Toscano J.P., et al. Quality of care for gout in the US needs improvement. Arthritis Rheum 2007, 57:822-829.
2. Janssens H.J., Janssen M., van de Lisdonk E.H., et al. Limited validity of the American College of Rheumatology criteria for classifying patients with gout in primary care. Ann Rheum Dis 2010, 69:1255-1256.
3. Janssens H.J., Fransen J., van de Lisdonk E.H., et al. A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Intern Med 2010, 170:1120-1126.
4. Choi H.K., Al-Arfaj A.M., Eftekhari A., et al. Dual energy computed tomography in tophaceous gout. Ann Rheum Dis 2009, 68:1609-1612.
5. Choi H.K., Burns L.C., Shojania K., et al. Dual energy CT in gout: a prospective validation study. Ann Rheum Dis 2012.
6. Ottaviani S., Bardin T., Richette P. Usefulness of ultrasonography for gout. Joint Bone Spine 2012, 10.1016/j.jbspin.2012.01.012.
7. Ottaviani S., Richette P., Allard A., et al. Ultrasonography in gout: a case-control study. Clin Exp Rheumatol 2012, 30:499-504.
8. Ottaviani S., Allard A., Bardin T., et al. An exploratory ultrasound study of early gout. Clin Exp Rheumatol 2011, 29:816-821.
9. De Miguel E., Puig J.G., Castillo C., et al. Diagnosis of gout in patients with asymptomatic hyperuricaemia: a pilot ultrasound study. Annals Rheum Dis 2012, 71:157-158.
10. Howard R.G., Pillinger M.H., Gyftopoulos S., et al. Reproducibility of musculoskeletal ultrasound for determining monosodium urate deposition: concordance between readers. Arthritis Care Res (Hoboken) 2011, 63:1456-1462.
11. Krishnan E., Lessov-Schlaggar C.N., Krasnow R.E., et al. Nature versus nurture in gout: a twin study. Am J Med 2012, 125:499-504.
12. Sulem P., Gudbjartsson D.F., Walters G.B., et al. Identification of low-frequency variants associated with gout and serum uric acid levels. Nat Genet 2011, 9:1127-1130. 43.
13. So A., Thorens B. Uric acid transport and disease. J Clin Invest 2010, 120:1791-1799.
14. Kylin E. Studies of the hypertension-hyperglycemia-hyperuricemia syndrome. Zentralbl Inn Med 1923, 44:105-127.
15. Kim S.Y., Guevara J.P., Kim K.M., et al. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2010, 62:170-180.
16. Grayson P.C., Kim S.Y., LaValley M., et al. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011, 63:102-110.
17. Choi H.K., Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007, 116:894-900.
18. De Vera M.A., Rahman M.M., Bhole V., et al. Independent impact of gout on the risk of acute myocardial infarction among elderly women: a population-based study. Ann Rheum Dis 2010, 69:1162-1164.
19. Lyngdoh T., Marques-Vidal P., Paccaud F., et al. Elevated serum uric acid is associated with high circulating inflammatory cytokines in the population-based colaus study. PLoS One 2011, 6:e19901.
20. Martinon F. Mechanisms of uric acid crystal-mediated autoinflammation. Immunol Rev 2010, 233:218-232.
21. Lu B., Nakamura T., Inouye K., et al. Novel role of PKR in inflammasome activation and HMGB1 release. Nature 2012, 30:670-674. 488.
22. Shenoy A.R., Wellington D.A., Kumar P., et al. GBP5 promotes NLRP3-inflammasome assembly and immunity in mammals. Science 2012, 336:481-485.
23. Popa-Nita O., Rollet-Labelle E., Thibault N., et al. Crystal-induced neutrophil activation. IX. Syk-dependent activation of class Ia phosphatidylinositol 3-kinase. J Leukoc Biol 2007, 82:763-773.
24. Joosten L.A., Netea M.G., Fantuzzi G., et al. Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta. Arthritis Rheum 2009, 60:3651-3662.
25. Narayan S., Pazar B., Ea H.K., et al. Octacalcium phosphate crystals induce inflammation in vivo through interleukin-1 but independent of the NLRP3-inflammasome in mice. Arthritis Rheum 2011, 63:422-433.
26. Yagnik D.R., Evans B.J., Florey O., et al. Macrophage release of transforming growth factor beta1 during resolution of monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 2004, 50:2273-2280.
27. Zhang Y., Chen C., Choi H., et al. Purine-rich foods intake and recurrent gout attacks. Ann Rheum Dis 2012, 71:1448-1453.
28. Joosten L.A., Netea M.G., Mylona E., et al. Engagement of fatty acids with toll-like receptor 2 drives interleukin-1beta production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. Arthritis Rheum 2010, 62:3237-3248.
29. Holzinger D., Nippe N., Marketon K., et al. Toll-like receptor 4 agonists MRP 8 and MRP 14 act as endogenous enhancers of MSU-crystal-induced IL-1 secretion in vitro and reflect disease activity in gout patients in vivo. Ann Rheum Dis 2012, 71:86.
30. Schlesinger N., Alten R.E., Bardin T., et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012.
31. Schlesinger N., Mysler E., Lin H.Y., et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis 2011, 70:1264-1271.
32. Schumacher H.R., Evans R.R., Saag K.G., et al. Rilonacept (Interleukin-1 Trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results of the presurge-1 trial. Arthritis Care Res 2012, 10.1002/acr.21690.
33. Terkeltaub R., Schumacher H.R., Saag K.G., et al. Evaluation of rilonacept for prevention of gout flares during initiation of urate-lowering therapy: results of a phase 3, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010, 62:152.
34. Cho M., Ghosh P., Hans G., et al. The safety and efficacy of anakinra in the treatment of acute gout in hospitalized patients. Arthritis Rheum 2010, 62:163.
35. So A., De Smedt T., Revaz S., et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007, 9:R28.
36. Becker M.A., Schumacher H.R., Espinoza L.R., et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010, 12:R63.
37. Sundy J.S., Baraf H.S., Yood R.A., et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011, 306:711-720.